Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib

J Clin Oncol. 2014 Dec 1;32(34):e114-6. doi: 10.1200/JCO.2013.48.7462. Epub 2014 Feb 18.
No abstract available

Publication types

  • Case Reports
  • Clinical Trial, Phase II

MeSH terms

  • Adolescent
  • Antineoplastic Agents / administration & dosage*
  • Chemotherapy, Adjuvant
  • Child
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Protein Kinase Inhibitors / administration & dosage*
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors
  • Proto-Oncogene Proteins c-met / metabolism
  • Pyrrolidinones / administration & dosage*
  • Quinolines / administration & dosage*
  • Sarcoma, Alveolar Soft Part / diagnosis
  • Sarcoma, Alveolar Soft Part / drug therapy*
  • Sarcoma, Alveolar Soft Part / enzymology
  • Sarcoma, Alveolar Soft Part / secondary
  • Thigh
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • ARQ 197
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrrolidinones
  • Quinolines
  • MET protein, human
  • Proto-Oncogene Proteins c-met